Risks and Consequences of Chemotherapy-Induced Neutropenia, Clinical Cornerstone, vol.8, issue.5, pp.12-18, 2006. ,
DOI : 10.1016/S1098-3597(06)80054-2
Neutropenia-Related Costs in Patients Treated with First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer, Journal of Managed Care Pharmacy, vol.15, issue.8, pp.15669-682, 2009. ,
DOI : 10.18553/jmcp.2009.15.8.669
Chemotherapy-induced neutropenia, Cancer, vol.112, issue.2, pp.228-237, 2004. ,
DOI : 10.1002/cncr.11882
Management of febrile neutropenia: ESMO Clinical Practice Guidelines, Annals of Oncology, vol.21, issue.Supplement 5, pp.252-256, 2010. ,
DOI : 10.1093/annonc/mdq196
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer, pp.529-541, 2010. ,
update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours, p.2010 ,
Myeloid Growth Factors, J Natl Compr Canc Netw, vol.2, issue.7, pp.64-83, 2009. ,
DOI : 10.1182/blood-2003-06-2094
Dose-effect Relationship of Bolus 5-Fluorouracil in the Treatment of Advanced Colorectal Cancer, Acta Oncologica, vol.41, issue.6, pp.41525-531, 2002. ,
DOI : 10.1080/02841860214959
Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?, J BUON, vol.14, issue.2, pp.203-209, 2009. ,
Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study, Supportive Care in Cancer, vol.6, issue.23, pp.161299-1309, 2008. ,
DOI : 10.1007/s00520-008-0430-4
Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer, Gynecologic Oncology, vol.124, issue.2, pp.221-224, 2012. ,
DOI : 10.1016/j.ygyno.2011.10.003
Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy, Journal of Thoracic Oncology, vol.5, issue.9, pp.1397-1403, 2010. ,
DOI : 10.1097/JTO.0b013e3181eba7f9
Colony-Stimulating Factors for the Management of Neutropenia in Cancer Patients, Drugs, vol.15, issue.Supplement 1, pp.1-15, 2002. ,
DOI : 10.2165/00003495-200262001-00001
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with smallcell lung cancer, N Engl J Med, issue.3, pp.325164-170, 1991. ,
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients, Cancer, vol.85, issue.10, pp.2258-2266, 2006. ,
DOI : 10.1002/cncr.21847
GRANULOCYTE COLONY-STIMULATING FACTOR AND NEUTROPHIL RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION, The Lancet, vol.334, issue.8668, pp.891-895, 1989. ,
DOI : 10.1016/S0140-6736(89)91552-3
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy, European Journal of Cancer, vol.29, issue.3, pp.29-319, 1993. ,
DOI : 10.1016/0959-8049(93)90376-Q
Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review, Journal of Clinical Oncology, vol.25, issue.21, pp.253158-3167, 2007. ,
DOI : 10.1200/JCO.2006.08.8823
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis, The American Journal of Medicine, vol.112, issue.5, pp.406-411, 2002. ,
DOI : 10.1016/S0002-9343(02)01036-7
Use of Colony-Stimulating Factors With Chemotherapy: Opportunities for Cost Savings and Improved Outcomes, JNCI Journal of the National Cancer Institute, vol.103, issue.12, pp.979-982, 2011. ,
DOI : 10.1093/jnci/djr152
Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection, Annals of Internal Medicine, vol.147, issue.6, pp.400-411, 2007. ,
DOI : 10.7326/0003-4819-147-6-200709180-00010
PD06-04: Uptake and Economic Impact of First-Cycle Colony Stimulating Factor Use during the Adjuvant Treatment of Breast Cancer., Cancer Research, vol.71, issue.24 Supplement, pp.30806-812 ,
DOI : 10.1158/0008-5472.SABCS11-PD06-04
American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology, Journal of Clinical Oncology, vol.30, issue.14, pp.301715-1724 ,
DOI : 10.1200/JCO.2012.42.8375
update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Oncol, issue.19, pp.243187-3205, 2006. ,
The challenge of biosimilars, Annals of Oncology, vol.19, issue.3, pp.411-419, 2008. ,
DOI : 10.1093/annonc/mdm345
Follow-on biologics: challenges of the 'next generation', Nephrology Dialysis Transplantation, vol.20, issue.suppl_4, pp.31-36, 2005. ,
DOI : 10.1093/ndt/gfh1085
Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim, Biologicals, vol.38, issue.5, pp.557-566, 2010. ,
DOI : 10.1016/j.biologicals.2010.05.002
Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial, Annals of Hematology, vol.19, issue.Suppl 1, pp.971-978, 2010. ,
DOI : 10.1007/s00277-010-0973-6
URL : https://hal.archives-ouvertes.fr/hal-00549425
Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial, Annals of Hematology, vol.23, issue.Suppl 1, pp.927-933, 2010. ,
DOI : 10.1007/s00277-010-0961-x
URL : https://hal.archives-ouvertes.fr/hal-00535133
A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer, Onkologie, vol.33, issue.10, pp.33504-511, 2010. ,
DOI : 10.1159/000319693
Biosimilar rhG-CSFs: how similar are they?, Targeted Oncology, vol.8, issue.suppl 2, pp.3-16 ,
DOI : 10.1007/s11523-011-0187-4
Biosimilars: opportunity or cause for concern, J Pharm Pharm Sci, vol.10, issue.3, pp.405-410, 2007. ,
Biosimilar therapeutics-what do we need to consider? NDT Plus, pp.27-36, 2009. ,
Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association, Haematologica, vol.96, issue.7, pp.96942-947, 2011. ,
DOI : 10.3324/haematol.2011.045740
Nivestim summary of product characteristics, 2010. ,
Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy, Blood, vol.85, issue.9, pp.2619-2626, 1995. ,
Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients, British Journal of Haematology, vol.85, issue.3, pp.786-794, 1999. ,
DOI : 10.1046/j.1365-2141.1996.448987.x
Responsiveness to G-CSF before leukopenia predicts defense to infection in high-dose chemotherapy recipients, Blood, vol.104, issue.7, pp.1989-1994, 2004. ,
DOI : 10.1182/blood-2004-02-0628
Stability of Hospira filgrastim following changes to thermal and photic storage conditions, Eur J Hosp Pharm Sci, vol.17, issue.5, pp.50-57, 2011. ,
Research Capability Programme: background, vision, overview and glossary, 2008. ,
Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices, Journal of Managed Care Pharmacy, vol.13, issue.4, pp.337-348, 2007. ,
DOI : 10.18553/jmcp.2007.13.4.337
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim??? (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia, BMC Cancer, vol.13, issue.4, p.547, 2013. ,
DOI : 10.1182/blood-2004-02-0628
URL : https://hal.archives-ouvertes.fr/hal-01128970